Search
for
Sort by
Research 61–90 of 140
- The changing landscape of managing hair loss: a 30‐year perspective
- Cicatricial alopecia/lichen planopilaris-the Cleveland clinic foundation experience on evaluation, diagnosis and treatment
- The JAK/STAT signaling pathway: from bench to clinic
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
- Alopecia Areata: An Updated Review for 2023
- Alopecia Areata: Current Treatments and New Directions
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- Alopecia Areata: Pathogenesis, Diagnosis, and Therapies
- Immunopathology and Immunotherapy of Inflammatory Skin Diseases
- SIRT1 downregulation provokes immune-inflammatory responses in hair follicle outer root sheath cells and may contribute to development of alopecia areata
- Predictors and Management of Inadequate Response to JAK Inhibitors in Alopecia Areata
- Evidence on Hidradenitis Suppurativa as an Autoinflammatory Skin Disease
- Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
- Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
- Mechanisms of autophagy and their implications in dermatological disorders
- Baricitinib for the Treatment of Alopecia Areata
- Comparison of efficacy and safety of tofacitinib and azathioprine in patients with alopecia areata and variants: a double-blind, randomized controlled trial
- Alopecia areata
- Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
- Safety and Efficacy of Ritlecitinib for the Treatment of Patients with Alopecia Areata: A Systematic Review and Meta-Analysis of Controlled Trials
- Psychological Stress-Induced Pathogenesis of Alopecia Areata: Autoimmune and Apoptotic Pathways
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- Altered hypothalamus functional connectivity and psychological stress in patients with alopecia areata
- Janus kinase inhibitors for alopecia areata: A narrative review